Are there long term reproductive risks for females using lurbinectedin?

What reproductive risks do women face from lurbinectedin?

Lurbinectedin is an alkylating agent approved for treating small cell lung cancer. Alkylating agents as a class impair fertility and raise the risk of ovarian failure. Lurbinectedin itself has not been studied in long-term fertility trials, so clinicians often apply class-wide warnings.

How do alkylating agents affect female fertility?

Alkylating agents destroy rapidly dividing cells. They damage developing follicles in the ovaries, causing premature ovarian insufficiency and early menopause. Patients who receive multiple cycles often show reduced ovarian reserve and reduced egg count.

What happens if a woman becomes pregnant while on lurbinectedin?

Animal studies show fetal harm, including malformation and abortion. Human data remain limited. Current prescribing information directs women of childbearing age to use effective contraception during treatment and for at least six months after the last dose.

Can women recover fertility after stopping lurbinectedin?

Recovery depends on dose, duration, and age. Some women regain regular menses, but persistent amenorrhea and reduced fertility are common outcomes. Fertility preservation options such as egg freezing should be discussed before treatment begins.

Why are companies challenging this patent?

Jazz Pharmaceuticals holds the primary composition-of-matter patent for lurbinectedin that expires in 2033. [1]